Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials

2.

Lohse

MJ

.

Psychopharmaka

. In:

Schwabe

U

,

Ludwig

W

, editors.

Arzneiverordnungs-Report 2020

.

Berlin

:

Springer

;

2020

. p.

781

–

814

.

3.

Kern

DM

,

Cepeda

MS

,

Defalco

F

,

Etropolski

M

.

Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019

.

BMC Psychiatry

.

2020 Jan

;

20

(

1

):

4

.

4.

Gauthier

G

,

Guérin

A

,

Zhdanava

M

,

Jacobson

W

,

Nomikos

G

,

Merikle

E

, .

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis

.

BMC Psychiatry

.

2017 Jun

;

17

(

1

):

222

.

5.

Dold

M

,

Bartova

L

,

Rupprecht

R

,

Kasper

S

.

Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials

.

Psychother Psychosom

.

2017 Oct

;

86

(

5

):

283

–

91

.

6.

Bauer

M

,

Severus

E

,

Möller

HJ

,

Young

AH

.

Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines

.

Int J Psychiatry Clin Pract

.

2017 Sep

;

21

(

3

):

166

–

76

.

7.

Malhi

GS

,

Bell

E

,

Singh

AB

,

Bassett

D

,

Berk

M

,

Boyce

P

, .

The 2020 royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders: major depression summary

.

Bipolar Disord

.

2020 Dec

;

22

(

8

):

788

–

804

.

8.

Bollini

P

,

Pampallona

S

,

Tibaldi

G

,

Kupelnick

B

,

Munizza

C

.

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

.

Br J Psychiatry

.

1999 Apr

;

174

:

297

–

303

.

9.

Furukawa

TA

,

Cipriani

A

,

Cowen

PJ

,

Leucht

S

,

Egger

M

,

Salanti

G

.

Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis

.

Lancet Psychiatry

.

2019 Jun

;

6

(

7

):

601

–

9

.

10.

Rink

L

,

Braun

C

,

Bschor

T

,

Henssler

J

,

Franklin

J

,

Baethge

C

.

Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials

.

J Clin Psychiatry

.

2018 May/Jun

;

79

(

3

):

17r11693

.

11.

Braun

C

,

Adams

A

,

Rink

L

,

Bschor

T

,

Kuhr

K

,

Baethge

C

.

In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis

.

Acta Psychiatr Scand

.

2020 Dec

;

142

(

6

):

430

–

42

.

. Chichester; 2020 [cited 2021 Jun]. Available from: www.training.cochrane.org/handbook.

12.

Higgins

J

,

Thomas

J

,

Chandler

J

,

Cumpston

M

,

Li

T

,

Page

M

, .

Cochrane handbook for systematic reviews of interventions version 6.1

13.

World Health Organization

.

The ICD-10 classification of mental and behavioural disorders

: diagnostic criteria for research [Internet]. Geneve: WHO; 1993 [cited 2021 Jul 29]. Available from: https://apps.who.int/iris/handle/10665/37108.

14.

American Psychiatric Association

.

Diagnostic and statistical manual of mental disorders: DSM-5

.

Arlington

:

American Psychiatric Association

;

2013

.

15.

Hamilton

M

.

A rating scale for depression

.

J Neurol Neurosurg Psychiatry

.

1960 Feb

;

23

(

1

):

56

–

62

.

16.

Montgomery

SA

,

Asberg

M

.

A new depression scale designed to be sensitive to change

.

Br J Psychiatry

.

1979 Apr

;

134

:

382

–

9

.

17.

Henssler

J

,

Kurschus

M

,

Franklin

J

,

Bschor

T

,

Baethge

C

.

Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials

.

J Clin Psychiatry

.

2018 May/Jun

;

79

(

3

):

17r11470

.

18.

Huwaldt

JA

,

Paul

G

,

Steinhorst

S

.

Plot Digitizer 2015 [Internet]

. [cited

2021 June 13

]. Available from: http://plotdigitizer.sourceforge.net/.

19.

Higgins

JP

,

Altman

DG

,

Gøtzsche

PC

,

Jüni

P

,

Moher

D

,

Oxman

AD

, .

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

.

BMJ

.

2011

;

343

:

d5928

.

20.

Bech

P

,

Rafaelsen

OJ

.

The melancholia scale: development, consistency, validity and utility

. In:

Satorius

N

,

Ban

T

, editors.

Assessment of depression

.

Berlin

:

Springer

;

1986

. p.

259

–

69

.

21.

Perahia

DG

,

Pritchett

YL

,

Kajdasz

DK

,

Bauer

M

,

Jain

R

,

Russell

JM

, .

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder

.

J Psychiatr Res

.

2008 Jan

;

42

(

1

):

22

–

34

.

22.

Cohen

J

.

Statistical power analysis for the behavioral sciences

.

Hillsdale

:

L. Erlbaum Associates

;

1988

.

23.

Furukawa

TA

,

Barbui

C

,

Cipriani

A

,

Brambilla

P

,

Watanabe

N

.

Imputing missing standard deviations in meta-analyses can provide accurate results

.

J Clin Epidemiol

.

2006 Jan

;

59

(

1

):

7

–

10

.

24.

DerSimonian

R

,

Laird

N

.

Meta-analysis in clinical trials revisited

.

Contemp Clin Trials

.

2015 Nov

;

45

(

Pt A

):

139

–

45

.

25.

Rücker

G

,

Krahn

U

,

König

J

,

Efthimiou

O

,

Schwarzer

G

.

netmeta: network meta-analysis using frequentist methods. R package version 1.01 [Internet]

. [cited

2021 June 13

]. Available from: http://CRAN.Rproject.org/package=netmeta2019.

26.

R Core Team

.

R: a language and environment for statistical computing

.

Vienna

:

R Foundation for Statistical Computing

;

2019

.

27.

Ansseau

M

,

von Frenckell

R

,

Mertens

C

,

de Wilde

J

,

Botte

L

,

Devoitille

JM

, .

Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients

.

Psychopharmacology

.

1989

;

98

(

2

):

163

–

8

.

28.

Asnis

GM

,

Bose

A

,

Gommoll

CP

,

Chen

C

,

Greenberg

WM

.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study

.

J Clin Psychiatry

.

2013 Mar

;

74

(

3

):

242

–

8

.

29.

Bakish

D

,

Bose

A

,

Gommoll

C

,

Chen

C

,

Nunez

R

,

Greenberg

WM

, .

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

.

J Psychiatry Neurosci

.

2014 Jan

;

39

(

1

):

40

–

9

.

30.

Boyer

P

,

Montgomery

S

,

Lepola

U

,

Germain

JM

,

Brisard

C

,

Ganguly

R

, .

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

.

Int Clin Psychopharmacol

.

2008 Sep

;

23

(

5

):

243

–

53

.

31.

Brecht

S

,

Desaiah

D

,

Marechal

ES

,

Santini

AM

,

Podhorna

J

,

Guelfi

JD

.

Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial

.

J Clin Psychiatry

.

2011 Aug

;

72

(

8

):

1086

–

94

.

32.

Clayton

AH

,

Tourian

KA

,

Focht

K

,

Hwang

E

,

Cheng

RF

,

Thase

ME

.

Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial

.

J Clin Psychiatry

.

2015

;

76

(

5

):

562

–

9

.

33.

DeMartinis

NA

,

Yeung

PP

,

Entsuah

R

,

Manley

AL

.

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder

.

J Clin Psychiatry

.

2007 May

;

68

(

5

):

677

–

88

.

34.

Detke

MJ

,

Wiltse

CG

,

Mallinckrodt

CH

,

McNamara

RK

,

Demitrack

MA

,

Bitter

I

.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

.

Eur Neuropsychopharmacol

.

2004

;

14

(

6

):

457

–

70

.

35.

Emslie

GJ

,

Prakash

A

,

Zhang

Q

,

Pangallo

BA

,

Bangs

ME

,

March

JS

.

A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder

.

J Child Adolesc Psychopharmacol

.

2014 May

;

24

(

4

):

170

–

9

.

36.

Goldstein

DJ

,

Lu

Y

,

Detke

MJ

,

Wiltse

C

,

Mallinckrodt

C

,

Demitrack

MA

.

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

.

J Clin Psychopharmacol

.

2004 Aug

;

24

(

4

):

389

–

99

.

37.

Guelfi

JD

,

Ansseau

M

,

Corruble

E

,

Samuelian

JC

,

Tonelli

I

,

Tournoux

A

, .

A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients

.

Int Clin Psychopharmacol

.

1998 May

;

13

(

3

):

121

–

8

.

38.

Iwata

N

,

Tourian

KA

,

Hwang

E

,

Mele

L

,

Vialet

C

.

Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients

.

J Psychiatr Pract

.

2013 Jan

;

19

(

1

):

5

–

14

.

39.

Kamijima

K

,

Hashimoto

S

,

Nagayoshi

E

,

Koyama

T

.

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

.

Neuropsychiatr Dis Treat

.

2013

;

9

:

555

–

65

.

40.

Kanemoto

K

,

Matsubara

M

,

Yamashita

K

,

Tarao

Y

,

Inada

E

,

Sekine

T

.

Controlled comparison of two different doses of milnacipran in major depressive outpatients

.

Int Clin Psychopharmacol

.

2004 Nov

;

19

(

6

):

343

–

6

.

41.

Khan

A

,

Upton

GV

,

Rudolph

RL

,

Entsuah

R

,

Leventer

SM

.

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

.

J Clin Psychopharmacol

.

1998 Feb

;

18

(

1

):

19

–

25

.

42.

Liebowitz

MR

,

Manley

AL

,

Padmanabhan

SK

,

Ganguly

R

,

Tummala

R

,

Tourian

KA

.

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder

.

Curr Med Res Opin

.

2008 Jul

;

24

(

7

):

1877

–

90

.

. http://dx.doi.org/10.1186/1471-244X-13-94.

43.

Liebowitz

MR

,

Tourian

KA

,

Hwang

E

,

Mele

L

.

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

.

BMC Psychiatry

.

2013 Mar

;

13

:

94

44.

Mendels

J

,

Johnston

R

,

Mattes

J

,

Riesenberg

R

.

Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study

.

Psychopharmacol Bull

.

1993

;

29

(

2

):

169

–

74

.

https://clinicaltrials.gov/ct2/show/NCT00445679.

45.

Wyeth

.

NCT 00445679-Paroxetine-referenced study evaluating three doses of DVS SR in outpatients with MDD [Internet]

.

2013 [cited 2021 June 13]. Available from:

46.

Wyeth

.

NCT 00619619-Study evaluating desvenlafaxine succinate sustained-release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder [Internet]

.

2011

[cited 2021 June 13]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00619619.

47.

Perahia

DG

,

Wang

F

,

Mallinckrodt

CH

,

Walker

DJ

,

Detke

MJ

.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

.

Eur Psychiatry

.

2006 Sep

;

21

(

6

):

367

–

78

.

48.

Rudolph

RL

,

Fabre

LF

,

Feighner

JP

,

Rickels

K

,

Entsuah

R

,

Derivan

AT

.

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

.

J Clin Psychiatry

.

1998 Mar

;

59

(

3

):

116

–

22

.

49.

Septien-Velez

L

,

Pitrosky

B

,

Padmanabhan

SK

,

Germain

JM

,

Tourian

KA

.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

.

Int Clin Psychopharmacol

.

2007 Nov

;

22

(

6

):

338

–

47

.

50.

Tourian

KA

,

Padmanabhan

SK

,

Groark

J

,

Brisard

C

,

Farrington

D

.

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

.

Clin Ther

.

2009 Jun

;

31

(

Pt 1

):

1405

–

23

.

51.

Hosie

J

,

Martin

GDR

,

Mahapatra

S

,

N'Guyen

HD

,

Gros-Gean

J

,

Whitby

R

, .

VEN XR 367 (FDA) [Internet]

. [cited

2021 June 13

]. Available from: https://digitalcollections.ohsu.edu/concern/etds/z029p503q.

52.

Breilmann

J

,

Furukawa

TA

,

Becker

T

,

Koesters

M

.

Differences in the placebo response in duloxetine and venlafaxine trials

.

Acta Psychiatr Scand

.

2018 Jun

;

137

(

6

):

472

–

80

.

53.

Bartova

L

,

Dold

M

,

Kautzky

A

,

Fabbri

C

,

Spies

M

,

Serretti

A

, .

Results of the European Group for the Study of Resistant Depression (GSRD): basis for further research and clinical practice

.

World J Biol Psychiatry

.

2019 Jul

;

20

(

6

):

427

–

48

.

54.

Adli

M

,

Baethge

C

,

Heinz

A

,

Langlitz

N

,

Bauer

M

.

Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review

.

Eur Arch Psychiatry Clin Neurosci

.

2005 Dec

;

255

(

6

):

387

–

400

.

55.

Fava

GA

,

Cosci

F

,

Guidi

J

,

Rafanelli

C

.

The deceptive manifestations of treatment resistance in depression: a new look at the problem

.

Psychother Psychosom

.

2020

;

89

(

5

):

265

–

73

.

56.

Fava

GA

,

Benasi

G

,

Lucente

M

,

Offidani

E

,

Cosci

F

,

Guidi

J

.

Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review

.

Psychother Psychosom

.

2018

;

87

(

4

):

195

–

203

.

57.

Henssler

J

,

Heinz

A

,

Brandt

L

,

Bschor

T

.

Antidepressant withdrawal and rebound phenomena

.

Dtsch Arztebl Int

.

2019 May

;

116

:

355

–

61

.

58.

Cosci

F

,

Chouinard

G

.

Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications

.

Psychother Psychosom

.

2020

;

89

(

5

):

283

–

306

.

59.

Dunner

DL

,

Wohlreich

MM

,

Mallinckrodt

CH

,

Watkin

JG

,

Fava

M

.

Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses

.

Curr Ther Res Clin Exp

.

2005 Nov

;

66

(

6

):

522

–

40

.

60.

Whitmyer

VG

,

Dunner

DL

,

Kornstein

SG

,

Meyers

AL

,

Mallinckrodt

CH

,

Wohlreich

MM

, .

A comparison of initial duloxetine dosing strategies in patients with major depressive disorder

.

J Clin Psychiatry

.

2007 Dec

;

68

(

12

):

1921

–

1930

.

61.

Henssler

J

,

Kurschus

M

,

Franklin

J

,

Bschor

T

,

Baethge

C

.

Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials

.

J Clin Psychiatry

.

2017 Jan/Feb

;

79

(

1

):

15r10545

.

62.

Bschor

T

,

Kern

H

,

Henssler

J

,

Baethge

C

.

Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis

.

J Clin Psychiatry

.

2018 Jan

/Feb;

79

(

1

):

16r10749

.

63.

Hiemke

C

,

Bergemann

N

,

Clement

HW

,

Conca

A

,

Deckert

J

,

Domschke

K

, .

Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017

.

Pharmacopsychiatry

.

2018 Jan

;

51

(

1–2

):

9

–

62

.

64.

Zhou

X

,

Keitner

GI

,

Qin

B

,

Ravindran

AV

,

Bauer

M

,

Del Giovane

C

, .

Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis

.

Int J Neuropsychopharmacol

.

2015 May

;

18

(

11

):

pyv060

.

65.

Bauer

M

,

Adli

M

,

Baethge

C

,

Berghöfer

A

,

Sasse

J

,

Heinz

A

, .

Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms

.

Can J Psychiatry

.

2003 Aug

;

48

(

7

):

440

–

8

.

66.

Nelson

JC

,

Baumann

P

,

Delucchi

K

,

Joffe

R

,

Katona

C

.

A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression

.

J Affect Disord

.

2014 Oct

;

168

:

269

–

75

.

67.

Henssler

J

,

Bschor

T

,

Baethge

C

.

Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients

.

Can J Psychiatry

.

2016 Jan

;

61

(

1

):

29

–

43

.